Antares Pharma, Inc. (ATRS)

[jab91252]

Perhaps it depends on who is doing the talking. It was LeRoux Jooste today, who stated specifically to MTX rev's of between 100-200m peak opportunity - then he said not including potential sales of another indication like psoriasis.

"EWING, N.J. (AP) -- Shares of Antares Pharma Inc. climbed Wednesday after the drug developer said U.S. regulators will review its application for the potential rheumatoid arthritis and psoriasis treatment Otrexup.

Second perhaps is Paul may have been talking about not only MTX but "other" indications. I think the PDUFA on Oct will yield a two headed monster- maybe more??? Not trying to make excuses for the disconnect in numbers but this could be an explanation. These guys don't make up stuff is my point.

Just my two cents worth.
jab9